Patient death in gene therapy trial sends Ziopharm stocks falling
July 18, 2016Research and Development, Sales and Marketing ziopharm
Ziopharm Oncology has issued a statement following the death of a patient enrolled on a Phase I clinical trial for …
UK medical charity sells part of interest in MSD’s Keytruda for $150 million
July 15, 2016Research and Development, Sales and Marketing MSD, Merck, keytruda
UK medical research charity MRC Technology sold part of its royalty interest in US pharma major MSD’s (NYSE: MRK) immunotherapy …
Weekly Movers: CytRx, Coherus BioSciences, Juno Therapeutics…
July 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Coherus BioSciences, GW Pharmaceuticals, Sage Therapeutics, Share price, Shares, Stock Markets, cytrx, juno therapeutics
Shares in CytRx (Nasdaq: CYTR) lost nearly three-fourth in value after the company reported disappointing late-stage results for its lead …
Nice rejects United Therapeutics’ cancer drug
July 15, 2016Medical Communications, Research and Development NICE, United Therapeutics, Unituxin, neuroblastoma
The National Institute for Health and Care Excellence (Nice) rejected United Therapeutics’ (Nasdaq: UTHR) Unituxin (dinutuximab) in combination therapy to …
Bayer adds extra $2 billion to Monsanto bid
July 15, 2016Medical Communications, Sales and Marketing Bayer, monsanto
German pharma company Bayer (ETR: BAYN) have upped their bid for Monsanto (NYSE: MON) to $64 billion, putting pressure on …
Busy week at Juno Therapeutics ends with takeover of RedoxTherapies
July 15, 2016Medical Communications, Research and Development, Sales and Marketing juno therapeutics, redoxtherapies, takeover, vipadenant
Juno Therapeutics (NASDAQ: JUNO) has announced the acquisition of RedoxTherapies, adding its lead cancer drug candidate, vipadenant, to its portfolio.
Teva looking at up to $25 billion in bond sale to fund Allergan’s generic-unit buy – reports
July 15, 2016Medical Communications, Sales and Marketing Allergan, Financial, Teva, US regulators, bond sale, deal
Israeli drug firm Teva (NYSE: TEVA) is looking at a $20 billion to $25 billion bond sale in the US …
Shares drop at Santhera after FDA requires more trial data DMD drug
July 15, 2016Medical Communications, Research and Development Duchenne Muscular Dystrophy, FDA, santhera
Santhera Pharmaceuticals (SIX: SANN) has seen shares fall as much as 38% after the US Food and Drug Administration (FDA) …
Celgene says its Revlimid gets European approval to treat rare non-Hodgkin’s lymphoma
July 15, 2016Medical Communications, Research and Development, Sales and Marketing Celgene, European Commission, Revlimid, drug approval, drug trial, oncology
Celgene (Nasdaq: CELG) said the European Commission (EC) has approved Revlimid (lenalidomide) to treat a rare form of non-Hodgkin’s lymphoma.
Pfizer announces strong Phase III results for atopic dermatitis drug
July 14, 2016Research and Development Pfizer, anacor, atopic dermatitis, crisaborole, eczema
Pfizer (NYSE: PFE) has announced positive results from two pivotal Phase III studies for crisaborole in the treatment of mild …
Lilly, Boehringer Ingelheim to jointly study combination therapy for breast cancer
July 14, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, breast cancer, combination therapy, drug trial
US drug major Eli Lilly (NYSE: LLY) and Boehringer Ingelheim said they will jointly initiate early combination trials in breast cancer. The …
Amgen agrees deal to commercialise biosimilars in Japan with Daiichi Sankyo
July 14, 2016Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Daiichi Sankyo, Japan, biosimilars
Amgen (NASDAQ: AMGN) has agreed a deal with Daiichi Sankyo (TSE: 4568) that will see the pair commercialise nine biosimilars …
FDA recommends Novartis’s biosimilar for Enbrel in unanimous vote
July 14, 2016Research and Development, Sales and Marketing Enbrel, FDA, Novartis, Sandoz, biosimilar
Sandoz, a division of Novartis, has announced that a US Food and Drug Administration (FDA) advisory committee has recommended their …
Janssen’s New Drug Application for drug to treat intestinal worms gets US FDA priority review
July 14, 2016Manufacturing and Production, Research and Development, Sales and Marketing Johnson & Johnson, US FDA, WHO, drug trial, new drug application, regulation, soil-transmitted helminthiasis
Johnson & Johnson (NYSE: JNJ) said the US Food and Drug Administration (FDA) has granted Priority Review for its New …
US FDA committee recommends approval for Amgen’s biosimilar of AbbVie’s Humira
July 13, 2016Research and Development, Sales and Marketing AbbVie, Amgen, Humira, US FDA, biosimilar, drug approval, drug trial, inflammatory diseases, rheumatoid arthritis
One of the world’s bestselling drug may soon have competition in the US markets after the regulators backed a biosimilar …
US FDA lifts hold on Juno’s CAR-T therapy trials; shares jump
July 13, 2016Research and Development, Sales and Marketing Stock Price, US FDA, drug trial, juno therapeutics
Shares in Juno Therapeutics (Nasdaq: JUNO) jumped to close up almost 30% after the company said the US Food and …
Pfizer gets approval expansion from FDA for pneumonia vaccine
July 13, 2016Research and Development, Sales and Marketing FDA, Pfizer, Prevnar 13, adults, approval
The US Food and Drug Administration (FDA) has issued an expanded approval for Pfizer’s pneumococcal pneumonia vaccine Prevnar 13 to …
Scottish regulators back BMS’ Opdivo for lung cancer
July 13, 2016Research and Development, Sales and Marketing Bristol-Myers Sqibb, NICE, Scottish Medicines Consortium, lung cancer, opdivo, regulation
Bristol-Myers Squibb (NYSE: BMY) said the Scottish Medicines Consortium (SMC) has recommended cancer immunotherapy Opdivo (nivolumab) to treat advanced squamous …
Nice backs UCB’s Cimzia as alternate therapy for severe rheumatoid arthritis
July 13, 2016Research and Development, Sales and Marketing Cimzia, NICE, UCB, regulation, rheumatoid arthritis
The National Institute for Health and Care Excellence (Nice) has recommended UCB Pharma’s Cimzia (certolizumab pegol) on its own or …
AstraZeneca mulling a $10-billion bid for Medivation – report
July 12, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Celgene, Medivation, Pfizer, Xtandi, cancer drug, merger and acquisition
Anglo Swedish drug firm AstraZeneca (LSE: AZN) is considering a $10-billion takeover bid for Medivation (Nasdaq: MDVN), according to reports. …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
